Kymera Therapeutics CMO files initial Form 3

Kymera Therapeutics, Inc. filed an initial statement of beneficial ownership on Form 3 for Rooney Terence, who serves as Chief Medical Officer.

Accepted by SEC EDGAR 07/27/2026 - 06:25 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Kymera Therapeutics, Inc. filed an initial statement of beneficial ownership on Form 3 for Rooney Terence, who serves as Chief Medical Officer. This establishes him as a reporting officer under SEC rules and references an Exhibit 24 Power of Attorney relating to SEC filing authorizations.

Key Figures

Buy transactions reported: 0 Sell transactions reported: 0

2 metrics

Buy transactions reported 0 Total number of buy transactions in this Form 3

Sell transactions reported 0 Total number of sell transactions in this Form 3

Key Terms

Form 3, Power of Attorney, beneficial ownership

3 terms

Form 3 regulatory

"Filed as an initial statement of beneficial ownership on Form 3"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

Power of Attorney regulatory

"Remarks reference Exhibit 24 - Power of Attorney for SEC filings"

A power of attorney is a legal document that allows one person to make decisions and act on behalf of another person, often in financial or legal matters. It’s like giving someone a trusted helper or agent the authority to handle important tasks if you are unable to do so yourself. This matters to investors because it can impact how their assets are managed or transferred if they become unable to oversee their affairs.

beneficial ownership financial

"Initial statement of beneficial ownership on Form 3 for the officer"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the KYMR Form 3 filed for Rooney Terence represent?

The filing is an initial Form 3 statement of beneficial ownership for Rooney Terence as an officer of Kymera Therapeutics. It formally identifies him as a reporting person subject to SEC insider reporting requirements for future transactions in the company’s securities.

What position does Rooney Terence hold at Kymera Therapeutics (KYMR)?

Rooney Terence is reported as the Chief Medical Officer of Kymera Therapeutics, Inc. This officer title is disclosed in the Form 3 and is the basis for his status as a reporting person under SEC insider ownership and transaction reporting rules.

Does the KYMR Form 3 for Rooney Terence report any insider trades?

No, the Form 3 for Rooney Terence reports no buy or sell transactions. The structured data show zero buy and sell counts, indicating the filing serves as an initial ownership statement rather than a record of recent trading activity in Kymera’s securities.

Is Rooney Terence a 10% owner of Kymera Therapeutics (KYMR) in this filing?

Rooney Terence is not reported as a 10% owner of Kymera Therapeutics, Inc. The Form 3 data indicate the ten-percent-owner status box is not marked, while he is identified as an officer in his capacity as Chief Medical Officer.

What is Exhibit 24 in Kymera Therapeutics (KYMR) Chief Medical Officer’s Form 3?

The remarks reference Exhibit 24 – Power of Attorney. This exhibit typically authorizes designated individuals to sign and submit SEC filings on the reporting person’s behalf, streamlining future reporting obligations for the officer named in the Form 3.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Rooney Terence

(Last) (First) (Middle)

500 NORTH BEACON STREET

4TH FLOOR

(Street)

WATERTOWN MASSACHUSETTS 02472

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
07/27/2026

3. Issuer Name and Ticker or Trading Symbol
Kymera Therapeutics, Inc. [ KYMR ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit 24 - Power of Attorney

No securities are beneficially owned.

	/s/ Bruce Jacobs, as Attorney-in-Fact	07/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)